Dr. Olivier LOGET, DVM ERT, CapEval Pharma CEO, has more than 26 years of experience in pharma industry. He worked in toxicology departments since 1988 at Sanofi-Synthelabo (Paris area), Hazleton/Ricerca (Lyon), CIT (Evreux), Roche (Basel),  Addex Pharma (Geneva), OriBase Pharma (Montpellier) and CapEval Pharma (Geneva area). He is a Eurotox Registered Toxicologist with great expertise in drug development from clinical candidate selection through to entry into human. He joined Addex Pharma (Geneva) in 2006 as Head of Non-Clinical Drug Safety to participate in the IPO and to create, develop and lead this department until 2010, when he created CapEval Pharma and became CSO of OriBase Pharma.  As OriBase Pharma CSO (anticancer drug  development), he brought a great expertise in oncology drug development from candidate selection to clinical trials. At Roche he was Head of Animal Experimentation and Toxicology Project Leader. He was involved in several projects and Due Diligence opportunities.

He founded in 2010 CapEval Pharma, which he leads. He obtained his degree and doctorate in Veterinary Medicine at the University of Nantes (1990). He is author or co-author of more than 20 publications. He is co-founder of the European Society of Laboratory Animal Veterinarians and board director of the International Society of Ocular Toxicology. He is a lecturer teaching preclinical R&D, toxicology in drug development and ocular examination in several Research Institutes (INSERM, INRA), Universities and Veterinary Schools.

Expert Partner ADME/PK

arah Resina, Ph.D., graduated from the Montpellier II University in 2007. After her doctorate in Biology and Health, she joined the DMPK department of pharmaceutical company Sanofi-Aventis R&D and specialized in discovery and preclinical pharmacokinetics. Then she worked as Project Manager at Medesis Pharma, a biotechnology company dedicated to delivery nanotechnologies. She has been in charge of new oiled formulations development on several indications such as neuromuscular, metabolic and viral diseases.